Showing 120 of 120on this page. Filters & sort apply to loaded results; URL updates for sharing.120 of 120 on this page
Abstract 2961: AZD9592, an EGFR/cMET bispecific antibody-drug conjugate ...
Abstract 5736: AZD9592: An EGFR-cMET bispecific antibody-drug conjugate ...
(PDF) Abstract A109: AZD9291: an irreversible, potent and selective ...
In A General And Abstract Manner – JCDAT
Tilatamig Samrotecan | AZD9592 » ADC Review
100+ Abstract Examples to Download
First in Human Study of AZD9592 in solid tumors
Silver And Gold Abstract Art at Janet Simmons blog
AZD abstract technology logo design on white background. AZD creative ...
Orange Abstract Canvas
AZD abstract monogram shield logo design on white background. AZD ...
Abstract Art for Modern Spaces – Gallerist.in
Contemporary Abstract Art Painting
Large Abstract Art Love at Natasha Pruitt blog
Abstract Flower Painting Vintage at Brent Vangundy blog
【AACR 2023】ADC药物”角力”AACR-公司新闻-北京百普赛斯生物科技股份有限公司
Frontiers | Identifying optimal tumor-associated antigen combinations ...
tilatamig samrotecan (AZD9592) / AstraZeneca
Expanding new trends and technologies in ADC therapeutics
A Comprehensive Introduction to Bispecific ADCs | AxisPharm
阿斯利康的双抗ADC药物在华申请临床获受理（附双抗ADC汇总）_治疗_研究_肿瘤
The Evolving Paradigm of Antibody–Drug Conjugates Targeting the ErbB ...
【AACR 2023】ADC药物”角力”AACR - 自主发布 - 资讯 - 生物在线
靶向EGFR-cMET！阿斯利康ADC新药在中国申报临床
AACR2023| ADC药物及可用临床前动物模型 - 知乎
阿斯利康EGFR/c-Met ADC在华申报临床 3月9日，据CDE官网公示， 阿斯利康 ADC药物AZD9592在华申报临床。AZD9592 ...
阿斯利康三款1类新药在中国获批临床
EGFR敏感突变肺癌新药临床试验：EGFR/c-Met双靶点ADC药物AZD9592-印塔健康官网
Frontiers | A narrative review of antibody–drug conjugates in EGFR ...
2023AACR | ADC药物一览，多款双抗ADC亮相，恒瑞、石药、Seagen众星云集 2023年第114届美国癌症研究协会年会(AACR ...
AZD9291 inhibits tumor growth in xenograft models through degradation ...
Expression of AXL and sensitivity to AZD9291 in non-small-cell lung ...
In vivo antitumor efficacy of AZD9291 in subcutaneous xenograft models ...
阿斯利康最新财报：只用3天发现173款高质量抗体！肝癌CAR-T疗法的首个临床结果… 今日， 阿斯利康 （AstraZeneca）公司公布了 ...
双抗ADC全球在研格局 ADC药物在过去十多年间已取得了长足的进展，自2000年第一款药物Mylotarg上市，ADC已历经了三代。截止目前 ...
Tilatamig samrotecan (AZD9592) | EGFR/c-MET ADC | MedChemExpress
EGRET: A first-in-human study of the novel antibody-drug conjugate (ADC ...
P1.12-04 In Vivo Efficacy of AZD9592, an EGFR-cMET Bispecific ADC, in a ...
Tilatamig (AZD9592 Antibody) | EGFR/MET抗体 | MCE
阿斯利康也“Follow”第一三共
Tilatamig (AZD9592 Antibody) | EGFR/MET Antibody | MedChemExpress
AZD-9592 - Drug Targets, Indications, Patents - Synapse
阿斯利康双抗（EGFRxcMET)ADC有何启示医药新闻-ByDrug-一站式医药资源共享中心-医药魔方
阿斯利康EGFR/C-Met双靶点ADC——AZD9592专利公开，EGFR端亲和力高低成为重要考量因素医药新闻-ByDrug-一站式医药资源 ...
The combination of AZD9291 with a MEK inhibitor effectively inhibits ...
Home - 2026 ASCO® Annual Meeting
ISSX 2022 - Hypha Discovery
Additional characteristics of AZD9291 in vitro. A, AZD9291 demonstrates ...
奥西耐药后的“给力”答案：阿斯利康AZD9592，EGFR/c-MET双靶点ADC，客观缓解率超越70%，开启临床试验招募
药明系高管创立，双抗ADC黑马藏不住了_医药_李竞_博士
Frontiers | Targeting tumor-associated macrophages with STING agonism ...
AACR 2023：掌握双抗黄金矿脉，挖呀挖呀挖 - 知乎
医药魔方
AZD9291 binding mode and structure. | Download Scientific Diagram
(PDF) AZD9291-induced Acute Interstitial Lung Disease
AZD9291 inhibits EGFR phosphorylation and downstream signaling in ...
In vivo, combination of AZD9291 and selumetinib can overcome acquired ...
AZD9291 treatment is effective in erlotinib-resistant cells and induces ...
AZD9291 inhibits GBM tumorigenesis in vivo. a Mice bearing U87 ...
AZD5991 exhibits potent anti-tumor efficacy in MM models. a ...
Phase Ib study of afatinib plus standard-dose cetuximab in patients ...
AZD9291 inhibits NSCLC cell growth and decreases EGFRL858R/T790M ...
AZD9291-resistant PC9 cells show increased SerpinB5 levels after ...
Gene expression analysis of H1975 cells after AZD9291 treatment. a ...
Gefitinib and AZD9291 repress autophagic degradation. a A549 and HCC827 ...
Molecules | Free Full-Text | In Vivo Anticancer Activity of AZD3965: A ...
Aurora kinase B inhibitor AZD1152: repurposing for treatment of lupus ...
引领未来：双抗ADC的前沿进展-MedSci.cn
阿斯利康AZD9592获批临床，EGFR/c-MET双靶点药物究竟有何魅力？|观点_深圳热线
Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is ...
Popular Targets in the Bispecific ADC Pipeline-DIMA BIOTECH
AZD9829 / AstraZeneca
Graphical Abstracts: A Comprehensive Guide – Scientific News
Study on the Safety and Effectiveness of AZD5492 Alone or with Other ...
The third-generation EGFR inhibitor AZD9291 overcomes primary ...
Discovery of Clinical Candidate AZD0095, a Selective Inhibitor of ...
Aurora B Kinase Inhibition by AZD1152 Concomitant with Tumor Treating ...
Research methodology - Chemical abstracts - already available material ...
The combination of AZD9291 and HQP8361 enhances modulation of ...
AZD9496 demonstrates superior antitumor effects on ER-mutant expressing ...
c-Myc inhibition synergizes with AZD5991 in inducing apoptosis in AML ...
AZD9291 (Osimertinib) (Osimertinib; Mereletinib) | CAS 1421373-65-0 ...
TRAIL (a) and AZD9291 (b) suppress mTORC2 signaling while inducing ...
双抗ADC靶点介绍及在研药物研究进展-缔码生物
不超50亿！翰森进军双抗ADC，扩大与普米斯EGFR / cMet双抗合作 的欢迎关注 凯莱英 药闻2024年3月14日， 翰森制药 与普米斯 ...
